About Primaa
Founded in 2018, Primaa is a MedTech company offering an AI-based platform for automated and accurate cancer diagnosis in digital pathology. The company develops AI-powered software capable of detecting all cancer biomarkers with high speed and great accuracy, leveraging image analysis and deep learning technology. Primaa's solutions are designed by pathologists, for pathologists, focusing on improving the detection of major cancer biomarkers and guiding personalized treatment decisions. Their platform empowers pathologists with time-saving capabilities, accelerating case reviews and providing faster diagnoses through intelligent triage and case prioritization. The company's technology enhances diagnostic precision and confidence while advancing personalized medicine with more precise patient data. Primaa has developed the world's first CE-IVDR marked AI solution for dermatopathology and offers specialized tools for breast cancer diagnosis. Their solutions combine medical expertise with scientific validation to create clinically relevant applications that streamline pathology workflows and improve patient outcomes.
Mission & Story
Mission
Precision cancer diagnosis for precision care
Clinical Focus
Medical conditions and clinical areas addressed by Primaa.
Who It Serves
Milestones & Awards
Recent Milestones
March 2025: Partnership with Gestalt to revolutionize skin cancer detection. World's first CE-IVDR marked AI solution for dermatopathology launched. Multiple scientific publications in 2023-2025.
Awards & Recognition
World's first CE-IVDR marked AI solution for dermatopathology
Key Partnerships
Company Details
- Founded
- 2018
- Headquarters
- Paris, Île-de-France, France
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.